Aptimmune is a biotechnology company that specializes on developing mucosal vaccines for swine.
Aptimmune's investors include Arsenal Capital Partners, Cultivation Capital, Kemin Industries, The Yield Lab, Illinois Ventures.
Aptimmune is headquartered in St Louis, United States.
Aptimmune is a biotechnology company that specializes on developing mucosal vaccines for swine.
Aptimmune is at the Convertible Note stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Aptimmune — Funding & Investors." VCBacked, January 10, 2022, https://www.vcbacked.co/company/aptimmune. Accessed November 13, 2026.
VCBacked. (2022). Aptimmune — Funding & Investors. Retrieved November 13, 2026, from https://www.vcbacked.co/company/aptimmune
{{cite web |title=Aptimmune — Funding & Investors |url=https://www.vcbacked.co/company/aptimmune |website=VCBacked |access-date=November 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Aptimmune? Request a listing update